Patricia Inácio, PhD, science writer —

The Parkinson’s Foundation has announced a major expansion of its PD GENEration national study to make genetic testing and counseling more available for people with Parkinson’s disease in the U.S. The study (NCT04057794), which now has 23 sites, aims to enroll 15,000 people in all 50…

PreciseDx’s artificial intelligence (AI) platform shows an ability to accurately diagnose Parkinson’s disease in people before they develop severely evident symptoms, according to a new study. Conducted in collaboration with The Michael J. Fox Foundation (MJFF), the study’s findings support the platform’s potential to aid in diagnosing Parkinson’s and allowing patients to begin…

The Riverside Health & Rehabilitation Center, an affiliate of National Health Care Associates, now has a comprehensive program aimed at improving physical health and cognition for those with Parkinson’s disease. The program, housed at Riverside’s facility in East Hartford, Connecticut, is also open for people…

PolyCore Therapeutics has secured a seed investment to advance its lead compound PCT-3012, designed to treat motor symptoms in Parkinson’s disease without triggering levodopa-induced dyskinesia, or uncontrollable body movements. The investment, by Xontogeny and Ben Franklin Technology Partners, will enable studies supporting a potential…

Neuropore Therapies has received a $4.8 million grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop a small molecule that will block the activation of a protein receptor, called toll-like receptor 2 (TLR2), that fuels inflammation in people with Parkinson’s disease. The grant will support…

Lucy Therapeutics (LucyTx) has received a $4.9 million, two-year grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance work in the company’s mitochondrial platform that could lead to new Parkinson’s disease treatments. The award includes access to a network of MJFF staff and relevant foundation…

The Michael J. Fox Foundation (MJFF) has named Brit Mollenhauer, MD, a foundation scientific advisor, as the winner of this year’s J. William Langston Award in recognition of her contributions to Parkinson’s research in expanding avenues to new treatments. Mollenhauer’s work has focused on developing…

Practicing tai chi for a year improved gait and balance in early-stage Parkinson’s disease patients, improving both inflammation and metabolism as well as brain function, according to a recent study. The study, “Mechanisms of motor symptom improvement by long-term Tai Chi training in Parkinson’s disease patients,” was published…

Scientists have created a set of sensors that can help measure muscle strain and bulging while integrated in a wearable device, such as clothes, a feature that may be of use for people with Parkinson’s disease. The sensors could be used to remotely monitor disease progression, quantify the effects, and…

Using Cerevance’s oral CVN424 as an add-on therapy for Parkinson’s motor symptoms led to a significant and meaningful dose-dependent reduction in “off” time — periods when symptoms reappear or worsen — data from a Phase 2 study show. The trial also met its safety objectives, according to a…